SPR001
Phase 2Small molecule
SPR001 is one of 18 small molecule programs targeting Congenital Adrenal Hyperplasia. It is currently in Phase 2.
1
Indications
2
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Congenital Adrenal Hyperplasia
#DrugCompanyPhaseTrials
1Florinef
Alnylam PharmaceuticalsPhase 3
Femara
NovartisPhase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Eulexin
SSchering-Plough
Phase 3
Crenessity
Neurocrine BiosciencesPhase 3
Decadron
AAspen Global Incorporated
Phase 2
Teslac
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Lu AF95245
LundbeckPhase 2
Zytiga
Johnson & JohnsonPhase 1
Chronocort
NNeurocrine UK Limited
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SPR001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSpruce Biosciences